US23954D1090 - Common Stock
DAY ONE BIOPHARMACEUTICALS I
NASDAQ:DAWN (5/17/2024, 7:00:01 PM)
After market: 16.17 0 (0%)16.17
+0.14 (+0.87%)
Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in Brisbane California, California and currently employs 133 full-time employees. The company went IPO on 2021-05-27. The firm is focused on developing and commercializing targeted therapies for patients of all ages with life threatening diseases. The firm seeks to identify, acquire and develop product candidates that target high-value oncogenic drivers in cancers with unmet needs, with an initial focus on pediatric patients. Its lead product candidate, tovorafenib (DAY101), is an oral, brain-penetrant, highly selective type II pan-rapidly accelerated fibrosarcoma (pan-RAF), kinase inhibitor. Its second product candidate, pimasertib, is an oral, highly selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a well-characterized key signaling node in the MAPK pathway. The company has initiated an open-label, multicenter, Phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib monotherapy or combination therapy, which consists of two substudies, such as Substudy 1 and Substudy 2.
DAY ONE BIOPHARMACEUTICALS I
2000 Sierra Point Parkway, Suite 501
Brisbane California CALIFORNIA
P: 16504840899
CEO: Jeremy Bender
Employees: 133
Website: https://dayonebio.com/
DAWN stock results show that Day One Biopharmaceutical missed analyst estimates for earnings per share the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Day One Biopharmaceutical (NASDAQ:DAWN) just reported results for the first qua...
OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) ...
Here you can normally see the latest stock twits on DAWN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: